Skip to main content

How immunology research & treatments are evolving

Some of the most widely used and lucrative drugs of the past two decades have been injectable antibodies for conditions like psoriasis, arthritis and inflammatory bowel disease. Amid the cyclical refresh of drug pipelines that’s common in pharma, several companies are building broader strategies around immune disease research.

included in this trendline
  • Mirador picks up where immune drugmaker Prometheus left off
  • J&J says top drug prospect works across autoimmune disorders
  • NEJM paper fills in details on ‘remarkable’ CAR-T result in autoimmune disease
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.